ABUS R&D to Revenue
Arbutus Biopharma Corp · R&D to Revenue
ABUS R&D to Revenue
Latest reported179.23%period ending
ABUS FY R&D/Revenue (704.82% → 179.23%)
Latest values, visible window
High-resolution chart · PNG
ABUS r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 179.2303% | |
| 875.6603% | |
| 406.2621% | |
| 216.3254% | |
| 596.123% | |
| 713.5956% | |
| 958.2599% | |
| 981.3559% | |
| 585.9813% | |
| 4,086.6667% | |
| 207.0719% | |
| 258% | |
| 138.7613% | |
| 127.8167% | |
| 0% | |
| 103,665,632.5074% | |
| 0% | |
| 0% | |
| 52.941% | |
| 33.2661% | |
| 65.9333% | |
| 183.3787% | |
| 867.6804% | |
| 426.0269% | |
| 371.4174% | |
| 493.0147% | |
| 679.2655% | |
| 704.8183% |